Literature DB >> 18535022

Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study.

S Buechner1, M Moretti, A P Burlina, G Cei, R Manara, R Ricci, R Mignani, R Parini, R Di Vito, G P Giordano, P Simonelli, G Siciliano, W Borsini.   

Abstract

BACKGROUND: Anderson-Fabry disease (AFD) is an X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase A. Central nervous system (CNS) manifestations consist mainly of cerebrovascular events. Brain MRI results are often abnormal.
PURPOSE: The aim of the study was to describe CNS involvement in a group of Italian patients with AFD.
METHODS: Clinical and brain MRI data of 43 patients with AFD (25 men, 41.94+/-10.83 years old and 18 women, 52.48+/-17.50 years old) were analysed retrospectively. 17 male patients and 7 female patients were under treatment with enzyme replacement therapy (ERT).
RESULTS: All 43 patients had signs or symptoms of AFD. 16 men (64%) and 13 women (72%) demonstrated CNS involvement, although with varying severity. Overall, 6 men and 5 women had suffered from cerebrovascular accidents with an age at onset of 33.64+/-13.65 years and 53.68+/-11.71 years, respectively. Brain MR images were abnormal in 16/25 men and in 13/16 women. During CNS monitoring, some patients receiving ERT (5/17 men and 2/6 women) demonstrated neurological deterioration, especially those who had presented with cerebrovascular disease already before starting ERT.
CONCLUSIONS: The study demonstrated a high frequency of CNS involvement in homozygous and heterozygous AFD patients, often characterised by early age at onset and abnormal brain MRIs. At present, ERT is widely used; however, potential beneficent effects may be disguised by the progression of irreversible pathology in short-term follow-up. Therefore, primary and secondary prophylaxes of cerebrovascular disease are extremely important.

Entities:  

Mesh:

Year:  2008        PMID: 18535022     DOI: 10.1136/jnnp.2008.143693

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  37 in total

1.  Fabry disease with lenticular degeneration without pulvinar sign.

Authors:  Dokyung Lee; Jin Sug Kim; Da Rae Kim; Chun-Gyoo Ihm; Sung Sang Yoon
Journal:  Neurol Sci       Date:  2017-01-19       Impact factor: 3.307

Review 2.  Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.

Authors:  Saskia M Rombach; Bouwien E Smid; Gabor E Linthorst; Marcel G W Dijkgraaf; Carla E M Hollak
Journal:  J Inherit Metab Dis       Date:  2014-02-04       Impact factor: 4.982

Review 3.  Stroke and Fabry disease.

Authors:  Miguel Viana-Baptista
Journal:  J Neurol       Date:  2011-10-27       Impact factor: 4.849

4.  Brain MR Imaging Findings of Cardiac-Type Fabry Disease with an IVS4+919G>A Mutation.

Authors:  H-J Lee; S-C Hung; T-R Hsu; S-C Ko; T Chui-Mei; C-C Huang; D-M Niu; C-P Lin
Journal:  AJNR Am J Neuroradiol       Date:  2016-02-11       Impact factor: 3.825

5.  Detecting the effects of Fabry disease in the adult human brain with diffusion tensor imaging and fast bound-pool fraction imaging.

Authors:  Hunter R Underhill; Katie Golden-Grant; Lauren T Garrett; Stefanie Uhrich; Brandon A Zielinski; C Ronald Scott
Journal:  J Magn Reson Imaging       Date:  2015-05-27       Impact factor: 4.813

6.  Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy.

Authors:  Alessandro Salviati; Alessandro P Burlina; Walter Borsini
Journal:  Neurol Sci       Date:  2010-03-19       Impact factor: 3.307

Review 7.  Fabry disease-often seen, rarely diagnosed.

Authors:  Björn Hoffmann; Ertan Mayatepek
Journal:  Dtsch Arztebl Int       Date:  2009-06-26       Impact factor: 5.594

8.  Redefining the Pulvinar Sign in Fabry Disease.

Authors:  S Cocozza; C Russo; A Pisani; G Olivo; E Riccio; A Cervo; G Pontillo; S Feriozzi; M Veroux; Y Battaglia; D Concolino; F Pieruzzi; R Mignani; P Borrelli; M Imbriaco; A Brunetti; E Tedeschi; G Palma
Journal:  AJNR Am J Neuroradiol       Date:  2017-10-19       Impact factor: 3.825

Review 9.  Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features.

Authors:  Michela Ranieri; Gloria Bedini; Eugenio Agostino Parati; Anna Bersano
Journal:  Curr Treat Options Neurol       Date:  2016-07       Impact factor: 3.598

Review 10.  Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring.

Authors:  Björn Hoffmann
Journal:  Orphanet J Rare Dis       Date:  2009-10-11       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.